CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
peginterferon alfa-2a [Pegasys] +1 moredrug
Likely dose
peginterferon alfa-2a [Pegasys] 180 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01585324
NCT01585324Phase 4Completed
CompareCT.gov

Open, Multicenter Phase IV Study, Evaluating Drop of Hemoglobin in Association to the Rate of Sustained Virological Response in Chronic Hepatitis C Patients Treated With Ribavirin (Copegus®) in Combination With Standard Treatment (ANECO)

Hoffmann-La Roche·interventional·Posted Apr 25, 2012·Updated Jul 24, 2015

In Brief

A Phase 4 clinical trial evaluating peginterferon alfa-2a [Pegasys] and ribavirin [Copegus] for Hepatitis C, Chronic. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a). Patients will receive Copegus 1000 mg or 1200 mg orally daily and Pegasys 180 mcg subcutaneously weekly. Anticipated time on study treatment, depending on virological response, will be 48 or 72 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesCzechia
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 25, 2012
Enrollment StartJan 1, 2012
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.2 years ago

Interventions

peginterferon alfa-2a [Pegasys]drug

180 mcg subcutaneously weekly

ribavirin [Copegus]drug

1000 mg or 1200 mg orally daily